Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney ...

The company has seen sales hit by alternative compounded versions of its Ozempic and Wegovy drugs ... has allowed while supplies of Novo Nordisk’s approved drug have been in short supply.

April 14 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being distributed outside its authorized supply chain ...

Ozempic is now the only GLP-1 receptor agonist proven to reduce the risk of chronic kidney disease and people living with type 2 diabetes and chronic kidney disease. Novo Nordisk remains the ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Entering untapped markets, such as China, will be key to Novo Nordisk’s future growth. In more recent news, FDA has approved Ozempic to reduce risk of kidney disease and cardiovascular death in ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

Novo Nordisk, the Danish-headquartered manufacturer ... Health News // 11 hours ago Face mask can detect kidney disease via breath, study finds May 8 (UPI) -- A modified surgical face mask ...

Novo Nordisk ... versions of its Ozempic and Wegovy drugs, particularly in the U.S., a practice the U.S. Food & Drug Administration has allowed while supplies of Novo Nordisk's approved drug ...

April 14 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab said on Monday several hundred counterfeit units of its diabetes drug Ozempic ... caused deadly disease May 2, 2025 ...